AMS - Advanced Medical Solutions Group plc
LSE
->
Healthcare
->
Medical Instruments & Supplies
Winsford,
United Kingdom
Type: Equity
AMS price evolution
AMS
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $4.64 | $5.33 | $4.77 | |
| Inventory | ||||
| Total current assets | $20.37 | $20.08 | $19.57 | |
| Long term investments | ||||
| Property, plant & equipment | $25.29 | $22.99 | $22.55 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $47.36 | $44.46 | $43.55 | |
| Current liabilities | ||||
| Accounts payable | $0.35 | $0.3 | $0.25 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $10.05 | $6.76 | $5.25 | |
| Long term debt | $10.45 | $11.08 | $11.49 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $25.25 | $22.56 | $21.64 | |
| Shareholders' equity | ||||
| Retained earnings | $3.21 | $3.1 | $3.21 | |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $72.97 | $53.83 | ||
| Short term investments | ||||
| Net receivables | $4.13 | $20.89 | $19.5 | |
| Inventory | $19.3 | $21.02 | ||
| Total current assets | $18.72 | $114.97 | $97.17 | |
| Long term investments | ||||
| Property, plant & equipment | $23.8 | $27.44 | $30.06 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $43.96 | $249.51 | $238.56 | |
| Current liabilities | ||||
| Accounts payable | $0.23 | $4.88 | $6.79 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.17 | $17.01 | $14.71 | |
| Long term debt | $12.21 | $14.32 | $6.41 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.33 | $36.83 | $36.34 | |
| Shareholders' equity | ||||
| Retained earnings | $3.02 | $151.35 | $137.72 | |
| Other shareholder equity | $12.16 | $16.07 | ||
| Total shareholder equity | $212.68 | $202.21 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.7 | $4.92 | ||
| Cost of revenue | ||||
| Gross Profit | $2.82 | $1.91 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1.76 | $1.54 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.34 | $0.07 | ||
| Interest expense | -$0.18 | -$0.2 | ||
| Net income | ||||
| Net income | $0.41 | $0.19 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $21.32 | $19.75 | $108.6 | $86.8 |
| Cost of revenue | $47.53 | $40.76 | ||
| Gross Profit | $9.34 | $8.38 | $61.07 | $46.04 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $38.45 | $34.73 | ||
| Total operating expenses | $7.02 | $5.14 | $85.6 | $75.23 |
| Operating income | $23 | $11.56 | ||
| Income from continuing operations | ||||
| EBIT | $23 | $11.56 | ||
| Income tax expense | $0.43 | $0.96 | $4.5 | $1.5 |
| Interest expense | -$0.69 | -$0.72 | -$0.67 | -$0.69 |
| Net income | ||||
| Net income | $0.61 | $1.33 | $17.48 | $8.58 |
| Income (for common shares) | $17.48 | $8.58 | ||
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$6.18 | -$2.56 | -$0.21 | -$0.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.4 | -$1.31 | -$0.8 | -$2.66 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.2 | $1.34 | $0.75 | $4.19 |
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Net income | $17.48 | $8.58 | $18.92 | |
| Operating activities | ||||
| Depreciation | $7.07 | $5.74 | $4.84 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $31.02 | $21.51 | $21.7 | |
| Investing activities | ||||
| Capital expenditures | -$1.77 | -$2.35 | -$2.67 | |
| Investments | ||||
| Total cash flows from investing | -$0.39 | -$6.33 | -$26.77 | -$29.57 |
| Financing activities | ||||
| Dividends paid | -$3.85 | -$3.34 | -$3.01 | |
| Sale and purchase of stock | ||||
| Net borrowings | -$1.28 | -$1.81 | -$0.93 | |
| Total cash flows from financing | -$2.66 | -$5.11 | -$5.82 | -$3.58 |
| Effect of exchange rate | -$0.46 | $0.16 | -$0.19 | |
| Change in cash and equivalents | $4.19 | $19.14 | -$10.92 | -$11.64 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 13.12% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |